Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

Avelumab, an anti–programmed death‐ligand 1 monoclonal antibody approved for the treatment of metastatic Merkel cell carcinoma and platinum‐treated urothelial carcinoma, was initially approved with a 10 mg/kg weight‐based dose. We report pharmacokinetic (PK)/pharmacodynamic analyses for avelumab com...

Descripción completa

Detalles Bibliográficos
Autores principales: Novakovic, Ana M., Wilkins, Justin J., Dai, Haiqing, Wade, Janet R., Neuteboom, Berend, Brar, Satjit, Bello, Carlo L., Girard, Pascal, Khandelwal, Akash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027979/
https://www.ncbi.nlm.nih.gov/pubmed/31553054
http://dx.doi.org/10.1002/cpt.1645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027979/
https://www.ncbi.nlm.nih.gov/pubmed/31553054
http://dx.doi.org/10.1002/cpt.1645

Ejemplares similares